Physician profile
Luyi De Prada
NPI 1639480452
$4,603.13
in general payments reported to CMS, 2019-2025
25 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $173 · 2021: $484 · 2022: $476 · 2023: $909 · 2024: $722 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,874 · Education: $73.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,874.46 |
| Education | $73.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $920.36 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $513.68 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $447.82 | 2023-2025 | Filspari |
| Amgen INC. | $420.14 | 2019-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $293.99 | 2019-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $226.72 | 2021-2024 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $207.73 | 2021-2025 | |
| Vifor Pharma, INC. | $173.30 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.09 | 2024-2025 | Jardiance |
| Horizon Therapeutics Plc | $143.36 | 2021-2023 | Krystexxa |
| Vantive US Healthcare LLC | $128.34 | 2025 | |
| Baxter Healthcare | $123.64 | 2024 | |
| Novartis Pharmaceuticals Corporation | $102.86 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $101.43 | 2024-2025 | Tarpeyo |
| Akebia Therapeutics INC | $98.58 | 2019-2025 | Vafseo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $86.54 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $85.78 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $78.87 | 2021-2022 | |
| Daiichi Sankyo INC. | $72.75 | 2023 | Injectafer |
| Mallinckrodt Hospital Products INC. | $59.82 | 2020-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $52.03 | 2019-2023 | Ultomiris, Soliris |
| Takeda Pharmaceuticals U.S.A., INC. | $50.20 | 2021-2022 | |
| Novo Nordisk INC | $37.49 | 2025 | Ozempic, Rybelsus |
| Apellis Pharmaceuticals, INC. | $17.42 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $14.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luyi De Prada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.